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Strengths and limitations of this study
 ► This protocol combines the benefits (resuscitation 
and ex situ viability testing) of multiple machine 
perfusion modalities (dual hypothermic oxygenated 
machine perfusion (DHOPE), controlled oxygenated 
rewarming (COR) and normothermic machine per-
fusion (NMP)).
 ► The rewarming phase (COR) links DHOPE and NMP 
and helps to avoid sudden temperature shifts that 
may cause additional injury to an already compro-
mised donor organ.
 ► A newly developed perfusion fluid containing a hae-
moglobin-based oxygen carrier allows for perfusion 
at different temperatures, yet is not officially regis-
tered in the Netherlands.
 ► Initially, nationwide declined high-risk donor livers, 
which carry an increased risk of early graft failure 
due to primary non-function, early allograft dysfunc-
tion or post-transplant cholangiopathy, will be ac-
cepted for this machine perfusion protocol.
AbStrACt
Introduction Extended criteria donor (ECD) livers are 
increasingly accepted for transplantation in an attempt to 
reduce the gap between the number of patients on the 
waiting list and the available number of donor livers. ECD 
livers; however, carry an increased risk of developing primary 
non-function (PNF), early allograft dysfunction (EAD) or post-
transplant cholangiopathy. Ischaemia-reperfusion injury 
(IRI) plays an important role in the development of these 
complications. Machine perfusion reduces IRI and allows for 
reconditioning and subsequent evaluation of liver grafts. Single 
or dual hypothermic oxygenated machine perfusion (DHOPE) 
(4°C–12°C) decreases IRI by resuscitation of mitochondria. 
Controlled oxygenated rewarming (COR) may further reduce 
IRI by preventing sudden temperature shifts. Subsequent 
normothermic machine perfusion (NMP) (37°C) allows for ex 
situ viability assessment to facilitate the selection of ECD livers 
with a low risk of PNF, EAD or post-transplant cholangiopathy.
Methods and analysis This prospective, single-arm 
study is designed to resuscitate and evaluate initially 
nationwide declined ECD livers. End-ischaemic DHOPE 
will be performed for the initial mitochondrial and graft 
resuscitation, followed by COR of the donor liver to a 
normothermic temperature. Subsequently, NMP will be 
continued to assess viability of the liver. Transplantation 
into eligible recipients will proceed if all predetermined 
viability criteria are met within the first 150 min of NMP. 
To facilitate machine perfusion at different temperatures, 
a perfusion solution containing a haemoglobin-based 
oxygen carrier will be used. With this protocol, we aim 
to transplant extra livers. The primary endpoint is graft 
survival at 3 months after transplantation.
Ethics and dissemination This protocol was approved 
by the medical ethical committee of Groningen, 
METc2016.281 in August 2016 and registered in the Dutch 
Trial registration number
trial registration number NTR5972, NCT02584283.
IntroduCtIon
Increased use of ECd livers
Driven by the donor organ shortage, 
extended criteria donor (ECD) or subop-
timal quality livers are increasingly used for 
transplantation. These livers would have 
been refused for transplantation in the past, 
because of donor characteristics (advanced 
age, obesity, alcohol abuse and long intensive 









pen: first published as 10.1136/bmjopen-2018-028596 on 15 August 2019. Downloaded from 
2 de Vries Y, et al. BMJ Open 2019;9:e028596. doi:10.1136/bmjopen-2018-028596
Open access 
or graft pathology (steatosis, donation after circulatory 
death (DCD), elevated liver enzymes and history of liver 
trauma), but are nowadays accepted due to the shortage 
of suitable donor livers. ECD livers carry an increased risk 
of developing primary non-function (PNF), early allograft 
dysfunction (EAD) or post-transplant cholangiopathy.1 
These complications are difficult to predict, causing 
potentially transplantable ECD livers to be declined. 
It has been predicted that in the USA the donor liver 
discard rate will exceed 50% in the next two decades.2 3 In 
2016, in the Netherlands, 235 donation procedures were 
effectuated, yet 75 liver grafts were not used, equalling a 
discard rate of 32%.4
Machine perfusion as a tool to resuscitate ECd livers
In previous animal and preclinical human liver studies, 
machine perfusion has been applied as a tool to improve 
and evaluate donor livers prior to transplantation.5–7 
Many machine perfusion protocols exist, with varying 
temperature, perfusion solution and other character-
istics. Oxygenated hypothermic machine perfusion 
(HMP), which is performed at 4°C–12°C, aims to resus-
citate the mitochondria and sustain adenosine 5’-triphos-
phate (ATP) production through the supply of oxygen, 
while the cold keeps metabolic rates suppressed.8–10 
Schlegel et al have shown that 2 hours of oxygenated HMP 
is sufficient to replenish cellular energy stores.9 A pilot 
study by our research group, which included 30 DCD 
livers, has shown a 100% graft survival in the dual hypo-
thermic oxygenated perfusion (DHOPE) group (n=10), 
compared with 70% in the static cold storage (SCS) 
group (n=20). Furthermore, the incidence of non-anasto-
motic strictures (NAS) of the biliary tree was 10% in the 
DHOPE group, compared with 35% in the SCS group.10 
Based on these favourable results, our centre initiated a 
multicentre randomised controlled trial on DHOPE.
Several research groups have investigated the use of 
mid/subnormothermic machine perfusion (NMP) or 
controlled oxygenated rewarming (COR), performed at 
12°C–34°C.8 COR may function as a bridge between hypo 
and NMP, omitting a sudden temperature shift, but may 
also have an ischaemia-reperfusion injury (IRI) reducing 
effect.7 An abrupt temperature shift contributes to mito-
chondrial dysfunction, and is more pronounced during 
reperfusion after HMP, than after COR.7 11 COR has also 
been described to increase cellular energy content in a 
clinical study. Furthermore, in a clinical trial performed 
by the group in Essen, ECD graft survival was a 100% at 6 
months after transplantation in the COR group, whereas 
this was 85% in the SCS group.7 11
Machine perfusion as a tool to evaluate ECd livers
A more accurate determination of organ viability can 
be provided by NMP, which aims to resume metabo-
lism, requiring a more complex perfusion solution that 
includes an oxygen carrier and nutrients. Whereas NMP 
is a more complex method, metabolic parameters can 
be combined with indicators of graft injury to reflect 
the viability of the donor graft, giving the transplant 
team an indication whether the organ is suitable for 
transplantation.
Several research groups have proposed viability criteria 
to evaluate livers during NMP. Our group has suggested 
that 2.5 hours of NMP is sufficient to determine whether a 
liver is potentially transplantable.12 Livers that produced 
≥10 grams bile within 2.5 hours and ≥4 g in the preceding 
hour were associated with lower levels of transaminases, 
while glucose and lactate levels normalised. As a result, 
bile production was proposed as a viability criterion to 
identify potentially transplantable ECD livers.12 Watson 
et al were the first to report on end-ischaemic NMP of 
suboptimal human livers. Poor prognostic factors were an 
inability to maintain a normal pH, slow lactate fall and 
an increase in alanine aminotransferase (ALT) in the 
perfusion fluid.13 This group also indicated that if bile 
produced during NMP does not have a pH >7.45, there is 
a high risk of post-transplant cholangiopathy.14 The accu-
racy of bile pH, bicarbonate and glucose as biomarkers 
of severe bile duct injury was subsequently demonstrated 
by our group.15 16 Mergental et al proposed the following 
criteria after their first series of viability testing during 
NMP; perfusate lactate <2.5 mmol/L and sufficient bile 
production in combination with one of the following 
criteria; pH of perfusate >7.3, stable arterial and portal 
flow and homogeneous graft perfusion with soft consis-
tency of the parenchyma.17 The criteria for the VITTAL 
(Viability testing and transplantation of marginal livers) 
trial—a machine perfusion study using discarded livers 
in the UK—are similar, but do not include a minimal 
amount of bile production.18 The viability criteria of the 
current protocol are based on above-mentioned studies 
and our previous experience.
Perfusion solution with haemoglobin-based oxygen carrier
While sufficient amounts of oxygen can be dissolved in a 
perfusion solution at temperatures below 20°C, an oxygen 
carrier is necessary at higher temperatures. Red blood 
cell (RBC)-based perfusion solutions are, therefore, 
mostly used for NMP. RBCs, are, however, relatively scarce 
and cannot be used at hypothermic temperatures due to 
increased stiffness of the erythrocyte lipid membranes, 
which causes haemolysis. Furthermore, immune reac-
tions can be triggered while using RBC.19 20
Haemoglobin-based oxygen carriers (HBOCs) are 
alternatives for RBC. HBOC-201, a bovine-derived haemo-
globin product, has been used in both transfusion and 
machine perfusion studies.21–23 Recently, HBOC-201 has 
received FDA approval for the application in selected US 
centres to treat patients with a life-threatening anaemia 
who are not able/willing to receive RBC.21 22 Further-
more, several preclinical studies on NMP with an HBOC-
based perfusion solution have been performed. Laing et 
al have shown that reactive oxygen species production, 
cell necrosis and apoptosis are not more pronounced 
in HBOC perfused livers, compared with RBC perfused 
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box 1 Viability criteria
 ► Cumulative bile production of ≥10 mL during first 150 min of normo-
thermic machine perfusion (NMP) and ≥4 mL in the last hour (12).
 ► Lactate concentration in perfusate is (0.5–1.7 mmol/L) within 
150 min of NMP (13,17).
 ► Perfusion fluid pH is (7.35–7.45)within 150 min of NMP, without the 
need for repeated addition of NaHCO3 (13,17).
 ► Biliary pH of >7.45 within 150 min of NMP (15,29).
A liver graft will be deemed transplantable, if all of the criteria were met within 
150 min of NMP. As described in the Introduction and in the Methods section, 
criteria were based on previous studies and own experience, and reflect both 
hepatocellular and biliary viability.
Figure 1 Timeline of a regular liver transplantation versus the described protocol. The coloured bar depicts the machine 
perfusion protocol. The light blue bar represents 1 hour of DHOPE, the light orange bar represents 1 hour of COR and the pink 
bar represents NMP. If the liver is deemed transplantable within 150 min of NMP, NMP will continue (indicated in pink). Note that 
SCS and transport are approximate. Cold ischaemia time (CIT) is defined as the time from the start of cold in situ flush in the 
donor until reperfusion in the recipient. In the proposed protocol, CIT is defined as the time from the start of cold flush in situ 
until the start of machine perfusion. DHOPE, dual hypothermic oxygenated machine perfusion; NMP, normothermic machine 
perfusion; SCS, static cold storage.
production and lower (ALT) release during NMP with 
an HBOC-based perfusion solution, compared with an 
RBC-based perfusion solution.24 To facilitate machine 
perfusion at all temperatures and to eliminate the disad-
vantages of RBC usage, we have developed an HBOC-201-
based perfusion solution, which will be used for the here 
described machine perfusion protocol.
End-ischaemic ex situ machine perfusion protocol
In this protocol, we describe a prospective, single-arm 
study to resuscitate and evaluate initially nationwide 
declined ECD livers, using a combined protocol of 
DHOPE, COR and NMP. Initially, nationwide declined 
ECD livers are statically stored on ice and transported to 
our centre. DHOPE (8°C–10°C) will then be performed 
for 1 hour, to replenish ATP stores and diminish IRI. 
To facilitate a smooth transition from hypothermia to 
normothermia, livers will be slowly warmed up to 37°C 
during an hour, using COR. Subsequently, viability testing 
will be performed using NMP. If all of the predetermined 
viability criteria are met, the liver will be transplanted 
into an eligible recipient. Machine perfusion will be 
performed using a novel HBOC-201-based perfusion 
solution for all temperature phases.
MEthodS And AnAlySIS
Study design
This study is a prospective, single-arm, single-centre study. 
High-risk ECD livers that are declined for liver trans-
plantation by all Dutch liver transplant centres will be 
accepted for this trial. Typically, these donor livers are at 
increased risk of developing early graft loss due to PNF, 
EAD or NAS.
Organs will be allocated in compliance with Eurotrans-
plant (ET) rules, as described below. Organs will be 
preserved by SCS and transported to the University 
Medical Center Groningen (UMCG). On arrival, liver 
grafts will undergo DHOPE for 1 hour, followed by 1 hour 
of gradual rewarming until a temperature of 37°C is 
reached. During 2.5 hours of NMP, a viability assessment 
will be carried out. The liver will be labelled as transplant-
able if it meets all predefined viability criteria (box 1). 
If a liver meets all viability criteria, the transplant proce-
dure will proceed. If not, the liver will be offered back to 
ET for reallocation via the standard rules, or secondarily 
discarded if no other centre accepts the liver. Figure 1 
shows a timeline from procurement of the donor liver 
until transplantation or secondary discard/secondary 
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Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
Donor Bodyweight ≥40 kg HIV, hepatitis B or C positive
Split or partial liver grafts
Domino donor livers
Expected CIT ≥10 hours (20)




Fulminant liver failure or retransplantation for PNF
Participation in another trial which might influence outcomes of this trial
CIT, cold ischaemia time; PNF, primary non-function.
Surgical procedure, postoperative care and follow-up 
are identical to our routine liver transplantation prac-
tice. Patients will be continuously monitored during their 
hospital stay, and subsequently at routine visits (1 month 
and 3 months post-transplantation).25 After 3 months, 
graft survival will be evaluated to assess short-term compli-
cations; if the 3 months graft survival is less than 80%, the 
DHOPE-COR-NMP protocol will be considered unsuc-
cessful. A follow-up period of 3 months after transplanta-
tion is chosen, as PNF and EAD typically occur early after 
transplantation.26 Although the primary study endpoint 
graft survival is set at 3 months, all transplant recipients 
will be followed for at least 12 months to monitor for 
potential late complications.
Study objective and endpoints
The study described in this protocol aims to increase the 
number of transplantable donor livers, by resuscitating 
and evaluating initially nationwide declined ECD livers 
through a combined protocol of DHOPE, COR and NMP, 
using an HBOC-based perfusion solution.
Primary study endpoint
The primary endpoint is graft survival at 3 months after 
transplantation, where graft survival is defined as the 
absence of retransplantation or patient death. Both 
overall graft survival and graft survival censored for 
patient death (decease of the patient with a functioning 
graft) will be calculated.
Secondary study endpoints
 ► Graft and patient survival at 7 days and 3, 6 and 12 
months.
 ► PNF: absence of or minimal function of a liver graft 
after transplantation requiring retransplantation 
or leading to patient death within 7 days after the 
procedure.27
 ► EAD defined as one or more of the following criteria28:
Recipient serum aspartate aminotransferase (AST) 
and/or ALT >2000 IU/mL within the first 7 days after 
transplantation.
International normalised ratio (INR) of ≥1.6 on post-
operative day 7.
Recipient serum bilirubin levels of ≥171 μmol/L 
(10 mg/dL) on postoperative day 7.
 ► Development of clinically evident NAS (biliary stric-
tures in presence of symptoms such as elevated choles-
tatic enzymes, jaundice, cholangitis or pruritus). The 
number of interventions, such as endoscopic retro-
grade cholangiopancreatography, percutaneous tran-
shepatic cholangiography and drain and reoperation, 
will also be recorded.
 ► Biochemical analysis of graft function and IRI deter-
mined by postoperative serum levels of ALT, AST, 
alkaline phosphatase, gamma-glutamyl transferase, 
INR, lactate dehydrogenase, creatinine, platelets and 
total bilirubin at postoperative day 0–7 and 1 and 3 
months.
donor and recipient inclusion and exclusion criteria
Adult patients (≥18 years old) on the UMCG waiting list 
for a liver transplantation, who gave informed consent 
for this study, will be included. Inclusion and exclusion 
criteria are summarised in table 1. Eligible patients will be 
asked for informed consent during the screening process 
for liver transplantation by a hepatologist or researcher 
who is well known with the topic and assigned to this task 
by the delegation log.
Donor risk factors precluding safe transplantation, 
such as concurrent donor malignancy and a fibrotic/
cirrhotic macroscopic appearance of the liver, are consid-
ered exclusion criteria for the study. Furthermore, an 
agonal phase of >2 hours in DCD donors is considered an 
exclusion criteria, as it is national policy for procurement 
teams to withdraw if circulatory arrest has not occurred 
within 2 hours after withdrawal of life support. However, 
formally long donor warm ischaemia time is not an exclu-
sion criterion for this study.
Study procedures
Allocation procedure
After the liver of a donor in the Netherlands is declined 
by all three centres for regular transplantation following 
SCS alone, it will again be offered to our centre for 
inclusion in this protocol. In compliance with ET rules, 
livers will be allocated only to patients who are iden-
tified in the ET match list, based on the ET allocation 
rules. If a liver is not accepted for a patient who has 
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Table 2 Composition of the HBOC-201-based perfusion solution
Component Manufacturer/distributor Volume (mL)
HBOC-201 (Hemopure) HbO2 therapeutics, Pennsylvania, USA 1250
Gelofusine 4% B Braun, Melsungen, Germany 300
Albumin 20% Sanquin (Dutch blood bank) 250
Total parenteral nutrition (N14G30E) Hospital pharmacy 20
Addamel (trace elements) Fresenius Kabi, the Netherlands 10
Metronidazol (Flagyl) 5 mg/mL Baxter BV, Utrecht, the Netherlands 44
Sterile water B Braun, Melsungen, Germany 335
Insulin (NovoRapid) 100 IU/mL Novo Nordisk BV, Alphen aan den Rijn, the Netherlands 1
Cernevit (multi vitamins) Baxter BV, Utrecht, the Netherlands 2
Heparin (5000 IU/mL) Leo Pharma, Amsterdam, the Netherlands 2
Cefazolin 1 g/5 mL Baxter BV, Utrecht, the Netherlands 2
Taurocholic acid sodium salt 0.1% (1 mg/mL) Sigma Aldrich, Saint Louis, USA 7.7
Sodium bicarbonate 8.4% B Braun, Melsungen, Germany 35
KCl 1 mmol/mL B Braun, Melsungen, Germany 2
Glutathion (Tationil) 600 mg/4 mL Teofarma, Pavia, Italy 14
Total volume   2274.7
HBOC, haemoglobin-based oxygen carrier.
it will be allocated to another centre in one of the ET 
member states, according to ET allocation rules. ET and 
the national competent authority, the Dutch Transplanta-
tion Foundation (Nederlandse Transplantatie Stichting) 
have agreed that this protocol does not interfere with the 
regular allocation rules within the Netherlands or ET.
Preparation of the liver
The donor liver will be procured by one of the national 
multiorgan procurement teams. A standard surgical 
technique of in situ cold flush via the aorta with 4–7 L 
of University of Wisconsin (UW) cold storage solution 
(0°C–4°C), supplemented with 50 000 IU of heparin, 
will be used. If possible, the liver will be procured with 
a segment of 3–5 cm supratruncal aorta left attached to 
the coeliac trunk. The portal vein and common bile duct 
will be kept as long as possible. After procurement, the 
liver will be flushed via the portal vein with at least 1 L of 
UW cold storage solution. The cystic duct will be ligated, 
and the bile duct will be gently flushed with Belzer UW 
cold storage solution. The liver will be kept on ice (SCS) 
during transport to the UMCG where cannulation of 
the supratruncal aorta, portal vein, and bile duct will be 
performed. Furthermore, a small catheter will be inserted 
into the caval vein to collect venous perfusate samples.
Preparation of the perfusion solution
The perfusion solution containing HBOC-201 (table 2) 
and taurocholic acid for continuous infusion will be 
prepared under sterile conditions. The perfusion fluid 
was developed by our research group and has been used 
successfully in a preclinical study and the first clinical 
patients.24 25 For the purpose of this study, the perfu-
sion fluid was evaluated and tested for stability and 
compatibility by the pharmacy of the UMCG. Sterile 
preparation of the perfusion fluid will be conducted by 
the pharmacy of the UMCG. Taurocholic acid will be 
bought from Sigma Aldrich (Saint Louis, USA) and subse-
quently prepared for clinical use by pharmacy A 15 (the 
Netherlands), according to good manufacturing practice 
(GMP). Taurocholic acid will be continuously infused 
into the perfusion solution at a rate of 7.7 mg/hour from 
the start of the NMP phase. Furthermore, sodium bicar-
bonate can be added to the perfusion solution to correct 
a low pH.
Perfusion device
The Liver Assist (Organ Assist, Groningen, the Nether-
lands) is a CE marked (European Union Certification 
of Safety, Health and Environmental Requirements) 
machine perfusion device for ex situ perfusion of donor 
livers. The Liver Assist enables perfusion of the liver via 
the portal vein and hepatic artery, using two centrifugal 
pumps to provide continuous and pulsatile flow, respec-
tively. The system is pressure controlled, which provides 
auto regulation of the flow through the liver. The 
temperature can be set from 8°C to 37°C, and the pres-
ervation solution can be oxygenated by two hollow fibre 
membrane oxygenators.
Machine perfusion settings, viability assessment and subsequent 
transplantation
The Liver Assist will be primed with the HBOC-201-based 
perfusion solution. The machine perfusion protocol 
consists of 1 hour of DHOPE, followed by 1 hour of COR, 
and a minimum of 2.5 hours of NMP. During DHOPE, the 
fraction of inspired oxygen (FiO2) will be set at a 100% 
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Figure 2 Liver Assist pressure and temperature settings 
during DHOPE, COR and NMP. COR, controlled oxygenated 
rewarming; DHOPE, dual hypothermic oxygenated perfusion; 
HA, hepatic artery; NMP, normothermic machine perfusion; 
PV, portal vein.
box 2 laboratory investigations during follow-up
 ► Aspartate aminotransferase.
 ► Alanine aminotransferase.
 ► Alkaline phosphatase.
 ► Gamma-glutamyl transferase total bilirubin.
 ► Lactate dehydrogenase.
 ► Creatinine.
 ► Platelets.
 ► International normalised ratio.
COR and NMP, the FiO2 and O2 flow will be adjusted 
according to arterial partial pressure of oxygen (pO2) and 
venous saturation at the level of the suprahepatic inferior 
vena cava, where arterial pO2 should be 10.0–13.3 kPa and 
venous saturation 55%–75%. During COR, the tempera-
ture and arterial and portal pressure will be gradually 
increased, as depicted in figure 2.
During the first 2.5 hours of NMP, viability assessment will 
be carried out. The liver should match all of the criteria 
as described in box 1. These criteria were derived from 
literature and our own experience and reflect both hepato-
cellular and biliary viability.12 13 15 17 29 If the liver meets the 
predefined viability criteria, the recipient operation will be 
started. NMP of the liver will continue until recipient hepa-
tectomy is nearly complete. The liver will then be discon-
nected from the machine and immediately flushed with 2 L 
cold Belzer UW cold storage solution to remove the HBOC-
201-based perfusion fluid. If the liver does not meet the 
predefined viability criteria, the liver will be offered back to 
ET for re allocation or secondary discard.
Follow-up
After transplantation, patients will be monitored and 
treated according to standard post-transplant care. After 
discharge from the hospital, patients will be evaluated 
in the outpatient clinic up to 3 months. A summary of 
outcome parameters is shown in box 2.
Statistics
A total of 10 liver transplantations will be included in 
this study to determine if the proposed protocol can be 
applied safely. To transplant 10 livers, we expect to assess 
20 nationwide declined donor livers, as our preclinical 
study has indicated a potential recovery rate of at least 
50%.30 The intervention group will not be compared 
with a control group, as the livers that will be used are 
initially nationwide declined livers and it would not be 
ethical to transplant these livers directly. It is our main 
concern that the livers are safely transplanted and can 
match postoperative outcomes of regularly transplanted 
livers. Graft survival at 3 months after transplantation 
was chosen as the primary endpoint, as described in the 
‘ Methods section’. An acceptable graft survival would be 
at least >80%, based on data of regular transplantations.31 
If the 3-month graft survival rate is <80%, the trial will be 
stopped. Primary and secondary outcomes are described 
under ‘Study objective and endpoints’.
Collection, storage and analyses of data and samples
During machine perfusion and liver transplantation
 ► Perfusion characteristics, such as flow through the 
portal vein and hepatic artery, pressure settings for 
the portal vein and hepatic artery, resistance in the 
portal vein and hepatic artery, and temperature, will 
be recorded every 15 min.
 ► Every half hour arterial perfusate, and every hour 
venous perfusate, will be sampled for point of care 
analyses to evaluate liver function. Perfusate samples 
will be stored at −80°C for later laboratory anal-
yses, such as the assessment of hepatocellular injury 
markers and function.
 ► From COR/NMP onwards bile will be collected and 
stored at −80°C for later assessment of biliary injury. 
Furthermore, every half hour bile samples will be 
collected under mineral oil for point of care analysis 
to determine cholangiocyte function.
 ► Biopsies of liver parenchyma and common bile 
duct will be taken prior to machine perfusion, after 
machine perfusion and after reperfusion in the recip-
ient. Biopsies will be snap frozen or stored in formalin 
for paraffin embedding. H&E staining of paraffin 
biopsies will be performed to analyse hepatobiliary 
histological injury.
 ► Haemodynamic status (mean arterial pressure, heart 
rate and the use of inotropic medication) of the recip-
ient will be recorded prior to, during and after graft 
reperfusion.
Other study parameters: baseline values and parameters at 
inclusion
 ► Patient general demographics (age, gender, weight 
and height).
 ► Patient medical history, including:
 ► Model for end-stage liver disease score.
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 ► Symptoms of decompensated cirrhosis (ie, ascites, 
encephalopathy and hepatorenal syndrome).
 ► Viral status (ie, hepatitis A–E; cytomegalovirus (CMV); 
Epstein-Barr virus (EBV))
 ► Current hospitalisation status (home, hospital ward or 
ICU).
 ► Kidney function, as assessed by creatinine, glomerular 
filtration rate and the need for dialysis.
 ► Medication.
 ► Donor and liver graft characteristics (age, gender, 
weight before and after machine perfusion, height, 
cause of death, viral status, liver function, amount of 
steatosis and donor risk index).
 ► Reason for initial decline of the liver graft.
 ► In case of DCD, characteristics such as time interval 
between withdrawal of life support and circulatory 
arrest, time interval between circulatory arrest and 
start cold perfusion in situ, donor hepatectomy time.
 ► Surgical methods and technical difficulties or 
abnormalities.
 ► Cold ischaemia time, total preservation time 
(including SCS, DHOPE and NMP) and warm 
ischaemia time during implantation.
Monitoring and reporting
Serious adverse events will be reported to the accred-
ited medical ethical committee through the national 
web portal ToetsingOnline within 15 days after detec-
tion. Monitor visits via the Trial Coordination Centre 
(official institute for the monitoring of clinical trials in 
our centre) will take place after inclusion of 1, 5 and 10 
patients. During these visits, the monitor will examine the 
line listing of all adverse events.
Patient and public involvement
Patients and/or public were not involved in the design of the 
study and the selection of outcome parameters. No patients 
are involved in the recruitment and/or conduct of the study. 
Dissemination of the results of the study will be via scientific 
congresses and meetings, publication(s) in peer-reviewed 
scientific journal(s), and may include a press release for lay 
media. Participants in the trial will be informed about the 
outcomes through their local investigators.
dISCuSSIon
ECD livers are increasingly accepted for transplantation, 
due to the persistent shortage of suitable donor livers, 
leading to waiting list morbidity and mortality. Although 
ECD livers are increasingly used, many livers are still 
declined for transplantation because the estimated risk 
of early graft loss after transplantation, such as PNF, EAD 
or biliary complications, is considered too high.1 The 
current study aims to increase the number of livers suit-
able for transplantation by resuscitating and evaluating 
initially nationwide declined ECD livers with a combined 
machine perfusion protocol, using an HBOC-based 
perfusion solution.
The risks associated with participation in this study are 
related to the use of ECD livers. However, current litera-
ture and data from our own research group suggest that 
the proposed protocol will be beneficial for such livers, 
leading to acceptable outcome after transplantation. 
DHOPE has been described to resuscitate mitochondria, 
increase ATP concentration and reduce IRI of both the 
hepatocytes and cholangiocytes.8–10 Subsequently, COR 
prevents (mitochondrial) damage during and after a 
sudden temperature shift. Lastly, NMP will be used to 
assess viability.7 11
The primary endpoint of this study is based on the 
increased risk of ECD livers to develop PNF, EAD and 
post-transplant cholangiopathy.1 As these complications 
mostly occur within 3 months, graft survival at 3 months 
after transplantation was chosen as the primary outcome.26 
If graft survival is >80%, we will consider the proposed 
protocol as feasible and safe. A graft survival of <80% will be 
considered a cut-off point for this trial. These percentages 
are based on outcome of regular liver transplantations.31
One of the down sides of using high-risk ECD liver that 
were initially nationwide declined is the inability to add 
a control group. In our opinion, it would be unethical 
to transplant livers with a perceived high risk of compli-
cations, without resuscitating and evaluating these livers 
with machine perfusion prior to transplantation. For 
studies that include initially declined donor livers it is 
not unusual to not include a control group, as the risk of 
developing severe complications would be too high. The 
VITTAL trial has a similar design.18
To combine the machine perfusion phases, DHOPE, 
COR and NMP, an HBOC-201-based perfusion solution, will 
be used. In vivo side effects of first generation, HBOCs have 
been observed in the past. However, HBOC-201 recently 
received FDA approval for application in selected centres 
to treat patients with life-threatening anaemia, who are 
unable/unwilling to receive RBC.21 22 The use of HBOC-
201 for machine perfusion is an ex situ application and 
three different groups have reported favourable preclinical 
results after machine perfusion with an HBOC-201-based 
perfusion solution.19 23 24 To mitigate the potential side 
effects of HBOC-201 liver grafts will be flushed thoroughly 
with regular Belzer SCS solution after the machine perfu-
sion procedure.
In summary, with this protocol of sequential DHOPE, 
COR and NMP, we aim to resuscitate and select initially 
declined suboptimal donor livers for transplantation, in 
order to increase the number of transplantable livers. The 
application of the combined machine perfusion protocol 
will be considered safe and feasible if graft survival at 3 
months after transplantation of these initially declined 
donor livers is similar to that of regularly transplanted 
donor livers.
EthICS And dISSEMInAtIon
As described in the Methods section, the perfusion solu-
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to GMP, to ensure sterility and composition of the 
product. Monitoring of this study will be carried out by 
the trial coordination centre of the UMCG after inclusion 
of 1, 5 and 10 transplantations to ensure compliance with 
the protocol and patient safety in this trial.
Patient data will be coded and can only be decrypted via 
a secured document. After 15 years, data will be destroyed. 
All team members involved with this trial will adhere to the 
code of good research conduct. The results of this study 
will be submitted to a peer-reviewed international medical 
journal. Data of this study might be used for side studies.
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